SearchStax, the Search Experience company, has achieved a major milestone, surging into the Leaders quadrant of the G2 Grid® for Enterprise Search Software | Spring 2025 report, a 13-place leap from ...

Intalio, a global leader in Intelligent Information Management, successfully concluded its participation at Documation 2025 "Salon du management de l'information et des processus documentaires et ...

Despite these challenges, the benchmark indices ended the fiscal year with a gain of five percent. The midcap index performed ...

Shares of Phathom Pharmaceuticals fell after the company said Chief Executive Officer Terrie Curran has resigned and will be succeeded by SaNOtize's Steven Basta. The stock declined 22% to $4.88 on ...

Phathom on Tuesday said Steven Basta, who most recently served as CEO of anti-infective therapies company SaNOtize, has joined the Florham Park, N.J., biopharmaceutical company as president, CEO and a ...

The abrupt resignation announcement that came late on Friday, March 28, from Peter Marks, who heads the U.S. FDA's Center for ...

Quadrant Televentures Ltd share price was up by 2.27% from the previous closing price of ₹0.44. Who are peers of Quadrant Televentures Ltd? The peers of Quadrant Televentures Ltd are Bharti ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

Quadrant Televenture - Board Meeting Intimation for Board Meeting Intimation For Consideration Of Un-Audited Financial Result Quadrant Televentures Limited-has informed BSE that the meeting of the ...

Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The company has a market capitalization of $17.77 billion, a P/E ratio of -10.81, a P/E/G ratio of 1. ...

Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Jefferies analyst David Stanton maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report) today and set a price target of A$27.40. The company’s shares closed last ...